Principal Asset Management presents Principal Biotechnology Discovery Fund

Principal Asset Management presents Principal Biotechnology Discovery Fund

Kuala Lumpur, 22 September 2021 – Principal Asset Management Berhad (“Principal”) presents the Principal Biotechnology Discovery Fund (“Fund”). The Fund aims to achieve capital appreciation through investments in one collective investment scheme, which focuses on investing in biotechnology-related securities from emerging pharmaceuticals to life science companies. The Principal Biotechnology Discovery Fund has exposure to all market caps in biotechnology.

According to Munirah Khairuddin, CEO of Principal Asset Management, “Over the recent years, the biotechnology industry has grown from strength to strength and has it hands in many sectors such as healthcare, pharmaceuticals, agriculture, and genomics. Groundbreaking innovations are being created nearly every day in the space and have grown to be increasingly pivotal as we move towards a more advanced and sustainable future.” 

“The pandemic brought forth the resilience in the industry, especially in the medical sector. We have seen breakthroughs in vaccine development and have set a course of recovery both from a public health point of view and the economy. Through this fund, our customers will be able to experience and potentially reap the benefits from the innovation and progress in the Biotechnology sector,” she adds.

Through the Principal Biotechnology Discovery Fund, investors who seek medium to long-term capital appreciation would be able to benefit in line with the progress of among others, new drug discovery platforms and technologies which offer attractive fundamentals. It has exposure to investments primarily in biotechnology firms based in the United States (U.S.).  The fund is further strengthened by continuous research and development spending and will also benefit from increased healthcare demands as the global population ages. 

Designed as a feeder fund, the Fund will invest in a single collective investment scheme, namely Franklin Biotechnology Discovery Fund (“Target Fund”); a portfolio established under the Franklin Templeton Investment Funds (“FTIF”). The Fund will invest at least 95% of its net asset value in the Target Fund and may also invest up to 5% of its net asset value in liquid assets for liquidity purposes. 

The Fund has a multi-class structure of four share classes: Class AUD-Hedged, Class MYR-Hedged, Class SGD-Hedged, and Class USD. The fund will be priced with an initial offer of AUD 1.0000, MYR 1.0000, SGD 1.0000, and USD 1.0000 per unit, respectively. 

Learn more about the Principal Biotechnology Discovery Fund at or call 603-7718 3100.

About Principal Asset Management Berhad
Principal Asset Management Berhad, is a joint venture between Principal Financial Group®, a member of the FORTUNE 500® and a Nasdaq-listed global financial services company and CIMB Group Holdings Berhad, one of Southeast Asia’s leading universal banking groups.   

Established on 13 June 1994, Principal Asset Management Berhad is headquartered in Malaysia with footprint across Indonesia, Thailand and Singapore. In Malaysia, the company serves over 1 million investors across Southeast Asia.  It offers a wide variety of solutions to help more people save enough, protect enough and have enough with unit trust, retirement schemes, discretionary mandates and asset management expertise. 

With innovative ideas and real-life solutions, the company helps make financial security accessible to more investors in Southeast Asia. For more information, visit or
Principal, Principal and symbol design are trademark and service marks of Principal Financial Services, Inc. a member of the Principal Financial Group®.


Disclaimer: We recommend that you read and understand the contents of the Prospectus for Principal Biotechnology Discovery Fund dated 15 September 2021 which has been duly registered with the Securities Commission Malaysia (SC) before investing and that you keep the said Prospectus for your record. Any issue of units to which the Prospectus relates will only be made upon receipt of the completed application form referred to in and accompanying the Prospectus, subject to the terms and conditions therein. Investments in the Fund are exposed to risks. You should understand the risks, make your own risk assessment, and seek professional advice, where necessary. You can obtain copies of the Prospectus from the head office of Principal Asset Management Berhad, our website at or from any of our approved distributors. There are fees and charges involved in investing in the fund. We suggest that you consider these fees and charges carefully prior to making an investment. Investors have the right to request for the Prospectus, Product Highlights Sheet (PHS) and any other product disclosure document; and the documents should be read and understood before making any investment decision. Unit prices and income distributions, if any, may fall or rise. Past performance is not reflective of future performance and income distributions are not guaranteed. You are also advised to read and understand the contents of the Financing for Investments in Unit Trust Risk Disclosure Statement before deciding to obtain financing to purchase units. The registration of the Prospectus with the SC does not amount to nor indicate that the SC recommends or endorses the fund and the SC does not review advertisements produced by Principal.